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Background: MiR-133b is a muscle-specific microRNA; it has a role in the formation of cardiocytes and the
expression of myocardium ion channels by regulating target genes. Many human malignant tumors demonstrate a
low expression of miR-133b, as noted in colorectal, lung, esophagus and bladder cancers, but the role of miR-133b
in bladder cancer is unknown.
Methods: The expression of miR-133b in clinical bladder cancer specimens and adjacent normal tissues was
confirmed by stem-loop RT-PCR. We also analyzed the relationship between miR-133b expression and clinicopathological
factors of bladder cancer. Bcl-w and Akt1 protein expression in 41 bladder cancer specimens and adjacent normal tissues
was detected by Western blot. After transfection of miR-133b mimics or inhibitor into a T24 human bladder cancer cell
line, Bcl-w and Akt1 protein and mRNA expression were examined by Western blot and RT-PCR, respectively. The effect
of miR-133b on T24 cell proliferation and apoptosis was measured by CCK-8 tests and flow cytometry, respectively.
Results: The expression of miR-133b in bladder cancer tissues from 41 patients was significantly down-regulated
(P < 0.01); low expression of miR-133b was strongly associated with high-grade bladder cancer (P < 0.01). Bcl-w and
Akt1 proteins were significantly overexpressed in bladder cancer tissues versus adjacent normal tissues (P < 0.01 for
both). The expression of Akt1 and Bcl-w proteins and Akt1 mRNA, in T24 cells was significantly down-regulated or
up-regulated after transfection of miR-133b mimics or inhibitor, respectively; however, there was no significant
difference in Bcl-w mRNA expression. Transfection of HEK-293 T cells with miR-133b significantly suppressed a
luciferase-reporter containing the Bcl-w or Akt 1 3′-untranslated regions. MiR-133b mimics significantly inhibited
T24 cell proliferation, as well as increased T24 cell apoptosis (P < 0.05 and P < 0.01, respectively) while the miR-133b
inhibitor increased and decreased these, respectively (P < 0.05 for both).
Conclusions: MiR-133b may play a very important role in the proliferation and apoptosis of T24 cells by regulating
the expression of Bcl-w and Akt1.
Keywords: miR-133b, Bcl-w, Akt1, Bladder cancer, Proliferation, ApoptosisIntroduction
Bladder cancer is the most common malignant tumor of
the urinary system among Chinese. Most tumors (95%)
originate from the urothelium, but the pathogenesis of
bladder cancer has been unclear to date. While morbidity
due to bladder cancer has been increasing on a yearly
basis, the main treatment strategy has been surgery.
However, the recurrence rate of bladder cancer is high,* Correspondence: binwucmu@163.com
Department of Urology, Shengjing Hospital of China Medical University,
Shenyang, Liaoning 11004, P.R. China
© 2014 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and advanced cases are usually complicated by local inva-
sion and distal metastases, with poor outcomes. Under-
standing the molecular mechanisms of bladder cancer may
contribute to innovative treatments.
MicroRNAs (miRNAs) are short (20–24-nt) single
chain, non-coding RNAs that exist in eucaryons; their
expression differs according to the specific tissue and de-
velopmental stage of individuals. They also have important
regulatory functions during development and differenti-
ation. By targeting 3′ untranslated regions (3′UTRs) of
cognate mRNAs,miRNAs are involved in the translationtd. This is an Open Access article distributed under the terms of the Creative
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expression [1,2]. Some researchers have shown that more
than 50% of miRNA genes are located in regions related
to tumors. In addition, different kinds of tumors express
specific miRNAs, which may indicate that miRNAs have
oncogene- or anti-oncogene-like functions and may play a
role in the development of human tumors [3]. MiR-133b
is a type of muscle-specific microRNA; it takes part in the
formation of cardiocytes and the expression of myocardium
ion channels by regulating target genes. Many human ma-
lignant tumors, such as colorectal,lung, esophagus and
bladder cancer [4-7], express low levels of miR-133b; how-
ever, the role of miR-133b in bladder cancer is still unclear.
Bcl-w (also named BCL2L2) is a member of the Bcl-2
protein family and has a molecular weight of 22 kDa.
The Bcl-2 gene family is made up of many members, in-
cluding apoptosis inhibiting (e.g. Bcl-2, Bcl-xL, Bcl-w)
and apoptosis promoting proteins (e.g. Bax, Bad) [8],
which regulate programmed cell death. The proteins of
this family form dimers that are involved in DNA dam-
age or apoptosis in abnormal cells, such as tumor cells,
by breaking the balance between apoptosis promoting
and apoptosis inhibiting proteins [9]. Bcl-w shows higher
expression in some epithelium-derived tumors, such as
colorectal, cervical and breast [10-13]. However, reports
in the literature relating to the expression and function
of Bcl-w in bladder cancer are rare.
Akt1, a serine/threonine-protein kinase, also known as
Akt kinase, is involved in the regulation of various down-
stream signaling pathways, such as those of cell meta-
bolism, proliferation, survival, growth, and angiogenesis
[14,15]. A past study indicated that the Akt1 kinase was
most frequently activated during proliferation and sur-
vival pathways in cancer [16]. Kim et al. [17] reported
that [6]-shogaol reduced the constitutive phosphoryl-
ation of signal transducer and activator of transcription
3 (STAT3) and decreased the expression of cyclin D1/3,
which are target proteins in the Akt signaling pathway
in non-small cell lung cancer. Gai et al. [18] reported
that ursolic acid is important in inducing apoptosis, via
the suppression of Akt/NF-κB signaling in T24 human
bladder cancer cells, and this occurs in a dose-dependent
manner. Juanpere et al. [19] found that mutations in
FGFR3 and PIK3CA, singly or combined with RAS and
Akt1, were associated with Akt but not with MAPK path-
way activation in urothelial bladder cancer. Previous re-
ports have shown that Akt1 is involved in the regulation
of bladder cancer; however, it is unclear whether miR-
133b can regulate the expression of Akt1 in T24 human
bladder cancer cells.
According to past bioinformatics prediction results, we
speculated that Bcl-w and Akt1 might be target genes
for miR-133b. In this study, we detected the expression
of miR-133b, Bcl-w and Akt1 in clinical bladder cancertissues. The functional role of miR-133b in bladder cancer
and its influence on Bcl-w and Akt1 protein and mRNA
expression, and cell proliferation and apoptosis, was stud-
ied after transfection of miR-133b mimics or inhibitor into
a transitional human bladder carcinoma cell line, T24.
Results
MiR-133b expression is downregulated in bladder cancer
tissues
Expression levels of miR-133b were measured by stem-
loop RT-PCR in 41 bladder cancer specimens and their
corresponding adjacent normal tissues. Quantitative ana-
lysis indicated that miR-133b expression was signifi-
cantly decreased in bladder cancer specimens compared
to adjacent normal tissues (P < 0.01; Figure 1). These re-
sults implied that down-regulation of miR-133b may be
involved in human bladder cancer disease processes.
A negative relationship between miR-133b expression
and the pathological grading of bladder cancer
Bladder cancer specimens were divided into low expres-
sion (below average expression of 30.4) or high expres-
sion groups (expression levels higher than the average of
30.4) according to the relative expression of miR-133b,
normalized to U6 RNA. We found low miR-133b expres-
sion and high pathological grading were significantly nega-
tively correlated (P = 0.003; Table 1). However, there was
no significant association between miR-133b expres-
sion and gender, clinical stage or neoplasm recurrence
(Table 1). These results suggested miR-133b down-
regulation in human bladder cancer is strongly linked
to a high-grade pathology.
Determination of miR-133b sense and antisense transfection
efficiency
The relative expression of miR-133b in cells transfected by
miR-133b mimics (sense) and inhibitor (antisense) was
determined by qRT-PCR. We found the expression of miR-
133b were significantly increased and decreased after trans-
fection of miR-133b mimics (P < 0.01) and an miR-133b
inhibitor (P < 0.01), respectively, into T24 cells (Figure 2).
Bcl-w and Akt1 are putative targets of miR-133b according
to bioinformatics results
To gain a greater understanding of the role of miR-133b
in the pathogenesis of human bladder cancer, we looked
for its potential downstream targets. Six bioinformatics
algorithms were used to scan for possible targets and
two identified: Bcl-w and Akt1. Bcl-w was predicted to
be a target of miR-133b by five miRNA target prediction
algorithms (Diana-microT, miRanda, miRWalk, PICTAR,
TargetScan), and Akt1 was predicted to be a target of
miR-133b by PITA.
Figure 1 MiR-133b expression is downregulated in bladder cancer tissue. Expression levels of miR-133b were measured by stem-loop
RT-PCR in bladder cancer specimens and corresponding, adjacent normal tissues. U6 RNA was used as an endogenous normalizer and the relative
combined expression levels of miR-133b are shown. 2-ΔΔCt values ± SEM, n = 41, *P < 0.01.
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To verify the binding of miR-133b to the 3′-UTR of Bcl-w
and Akt1, a luciferase reporter assay was used. Results
showed that miR-133b significantly decreased the lucifer-
ase activity of the Bcl-w (Figures 3a and b) and Akt1
(Figures 3c and d) 3′-UTRs in HEK-293 T cells (P < 0.01
for both), but not mutant sequences of the 3′-UTR of
Bcl-w and Akt1. These results indicated that miR-133b
bound specifically to the 3′-UTR of Bcl-w and Akt1 as
predicted.
Upregulated Bcl-w and Akt1 protein expression in bladder
cancer tissue
Bcl-w and Akt1 protein expression was detected by
Western blot in 41 bladder cancer specimens and adjacent
normal tissues. We found that the combined expressions
of Bcl-w (Figure 4) or Akt1 (Figure 5) proteins were signifi-
cantly increased in bladder cancer specimens compared toTable 1 The relationship between miR-133b expression
and clinicopathological characterisics of bladder cancer
Charactistics n = 41 MiR-133b level P
valueHigh (%) Low (%)
Gender
Male 29 11(64.5) 18(75) 0.475a
Female 12 6(35.3) 6(25) 0.187a
Clinical stage
Ta-T1 (non-invasive) 24 12 012
T2-T4 (invasive) 17 5 12 0.003b*
Pathological grading
Low level 19 13 6
High level 21 4 17
Neoplasm recurrence
Early-onset 25 10 15 0.812a
Recurrent 16 7 9
aChi-square test, bSided Fisher’s exact test, *P < 0.01.adjacent normal tissues (P < 0.01 for both). These results
suggest roles for Bcl-w and Akt1 in the pathogenesis of
human bladder cancer.Effect of miR-133b on Bcl-w and Akt1 mRNA and protein
expression in T24 human bladder cancer cells
The effects of miR-133b mimics or an inhibitor on levels
of Bcl-w and Akt1 mRNA and protein in a human blad-
der cancer cell line, T24, were studied. Transfection of
miR-133b-sense or miR-133b-antisense into T24 cells
caused Akt1 mRNA expression to be significantly down-
regulated or up-regulated (P < 0.05 for both), respectively
(Figures 6b and d); however, there was no significant dif-
ference in Bcl-w mRNA expression (Figures 6a and c).
Transfection of miR-133-sense into T24 cells caused
Bcl-w (Figures 6e and ) and Akt1 (Figures 6g and h) protein
expression to be significantly down-regulated (P < 0.05 for
both; Figures 6e and f). Transfection of miR-133b-antisense
into T24 cells caused Bcl-w (Figures 6i and j) and Akt1
protein (Figures 6k and l) expression to be significantly
up-regulated (P < 0.05 for both). These results indicate
that miR-133b down-regulates Akt1 mRNA and protein,
and Bcl-w protein, but not its mRNA.MiR-133b inhibits cell proliferation of T24 cells
The effect of miR-133b on T24 cell proliferation was
studied. Cell proliferation assays were performed at 12 h,
24 h, 48 h and 72 h after miR-133b-sense or miR-133b-
antisense transfection of T24 cells. The cell proliferation
of untreated or miR-133b-sense-NC transfected T24 cells
was significantly greater compared to miR-133b-sense
transfected cells (P < 0.05; Figure 7A). The cell prolifera-
tion of untreated or miR-133b- antisense -NC transfected
T24 cells was significantly less compared to miR-133b-
antisense transfected cells (P <0.05; Figure 7B). These
results indicate that miR-133b expression in T24 cells
inhibits their proliferation.
Figure 2 Transfection of T24 cells with miR-133b sense and antisense. The relative expression of miR-133b normalized to U6 RNA was
determined by qRT-PCR. (a) MiR-133b expression was significantly increased after miR-133b mimics’ transfection into T24 cells. (b) MiR-133b
expression was significantly decreased after miR-133b inhibitor transfection into T24 cells. *P < 0.01.
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In this study, Annexin V-FITC double staining flow cy-
tometric analysis was performed to evaluate the effect
of miR-133b on apoptosis in T24 cells. Apoptosis was
determined 24 h after transfection. Compared witha b
dc
Figure 3 Bcl-w and Akt1 as target genes of miR133b. (a) Schematic dia
(b) Luciferase reporter assays in untreated HEK-293 T cells, or cotransfected w
miR-133b negative control (NC). *P < 0.01 (c) Schematic diagram of the predic
assays in untreated HEK-293 T cells, or cotransfected with wild type (wt) or m
(NC). *P < 0.01.miR-133b-sense transfected cells (16.47%), the apop-
tosis rate of untreated cells (1.95%) was significantly
less (P < 0.01; Figure 8a). Compared with miR-133b-
antisense transfected cells (1.25%), the apoptosis rate
of untreated cells (2.14%) was significantly greater (P < 0.05;gram of the predicted miR-133b binding site in the Bcl-w 3′-UTR.
ith wild type (wt) or mutant (mut) Bcl-w 3′-UTR, and miR-133b or
ted miR-133b binding site in the Akt1 3′-UTR. (d) Luciferase reporter
utant (mut) Akt1 3′-UTR, and miR-133b or miR-133b negative control
a b
Figure 4 Bcl-w expression is upregulated in bladder cancer tissue. (a) Bcl-w protein expression was determined by Western blot in bladder
cancer (BC) and normal (N) tissues. (b) Optical density values for combined Bcl-w protein relative to GAPDH in bladder cancer (BC) and normal
(N) tissues. n = 41. *P < 0.01.
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apoptosis in T24 cells.
Discussion
The development of epigenetics, accounting for 99% of the
human genome’s non-coding sequences, has attracted con-
siderable attention by scientists, with miRNA research be-
coming a significant hotspot in recent years [20-22]. As
non-coding, small molecule RNAs, miRNAs are involved in
many important physiological and pathological processes,
such as cell proliferation, development, differentiation, virus
infection and tumorigenesis, and are widely dysregulated in
various cancers [23-26]. MiRNA exerts its functions in a
manner similar to oncogenes or tumor suppressor genes:
tumor development and progression occur by the regula-
tion of target genes. MiRNA-induced oncogene functions
are often highly expressed in tumors, and miRNA-induced
tumor suppressor genes often show low or no expression
[27-29]. An miRNA can regulate multiple target genes,
and a target gene can also be regulated by a number of
miRNAs; both miRNA and target gene form a complex
regulatory network, which plays an important role in the
occurrence and development of human tumors.a b
Figure 5 Akt1 protein expression is upregulated in bladder cancer tis
bladder cancer (BC) and normal (N) tissues. (b) Optical density values for co
normal (N) tissues. n = 41. *P < 0.01.Recent studies have shown that the expression of miR-
133b is abnormal in many tumors. Masayuki et al. [30]
found that the expression of miR-133b was significantly
lower in esophageal squamous cell carcinoma; the prolif-
eration and invasion of a carcinoma cell line could be
inhibited after miR-133b transfection. In addition, they
also found that miR-133b could affect the biological be-
havior of the tumor through regulating gene expression
of FSCN1. Chiyomaru et al. [31] reported that miR-145
and miR-133a could influence the biological behavior of
bladder cancer cells by also regulating the expression of
FSCN1. We therefore speculated that miR-133b, whose
nucleotide sequences are similar to those of miR-133a,
may also play an important regulatory role in bladder
cancer. Hu et al. [32] found that the expression of miR-
133b was significantly decreased in colorectal cancer
and in colorectal cancer cell lines SW-620 and HT-29;
furthermore, it was found that miR-133b played an im-
portant role in vivo and in vitro by regulating the tyro-
sine kinase receptor, c-Met.
In this study, we examined expression levels of miR-133b
in bladder cancer tissues from 41 patients by RT-PCR and
found miR-133b was significantly down-regulated insue. (a) Akt1 protein expression was determined by Western blot in







Figure 6 (See legend on next page.)
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Figure 6 Effect of miR-133b mimics and inhibitor on Bcl-w and Akt1 mRNA and protein levels in a T24 human bladder carcinoma cell
line. T24 cells were untreated or treated with miR-133b sense or miR-133b sense normal control (NC) (a, b, e, f, g, h) or with miR-133b antisense
or miR-133b antisense normal control (NC) (c, d, i, j, k, l). Bcl-w (a, c) Akt1 (b, d) mRNAs were measured by qRT-PCR. Bcl-w (e, f, i, j) or Akt1
(g, h, k, l) proteins were measured by Western blot. *P < 0.05.
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vious research. Our results suggested miR-133b might
regulate certain oncogenes to inhibit tumorigenesis.
We further analyzed the relationship between the ex-
pression of miR-133b and clinicopathological factors,
and found that a lower expression level of miR-133b
was strongly associated with high-grade bladder cancer.
However, miR-133b and gender, clinical stage and neo-
plasm recurrence showed no significant correlation.
These findings support the idea that miR-133b may be
an important regulator in bladder cancer.
In our study, CCK-8 tests and flow cytometry were
used to evaluate the effects of miR-133b on cell prolifer-
ation and apoptosis of T24 cells, respectively. We found
that miR-133b overexpression caused T24 cell growth
inhibition and apoptotic enhancement. Thus, we hypoth-
esized that miR-133b may function as a tumor suppres-
sor, and the abnormal expression of miR-133b might be
an important factor in bladder cancer incidence.
As a member of the BCL2 family, Bcl-w is able to inhibit
cell apoptosis. Recently, Bcl-w was found to be highly
expressed in some epithelial tumors. Lee et al. reported
that Bcl-w could inhibit tumor cell apoptosis by blocking
the SAPK/JNK pathway in gastric adenocarcinoma [33].
Bae et al. found that Bcl-w promotes gastric cancer cell in-
vasion by inducing matrix metalloproteinase-2 expression
via phosphoinositide 3-kinase (PI3 kinase), Akt, and Sp1
[34]. Guo et al. [35] reported that Bcl-w was observed in
most human colon adenocarcinoma compared to normal
tissues, which suggested that Bcl-w was involved in the
regulation of colorectal cancer. The PI3 kinase-Akt path-
way is frequently activated in cancer. Recent reports have
identified that abnormal methylation of the Akt1 genea
Figure 7 Effect of miR-133b on proliferation of T24 cells. (a) T24 cells
(NC) or miR-133b sense (S) for up to 72 h. (b) T24 cells were untreated or t
antisense (AS) for up to 72 h. Cell proliferation was measured by CCK-8. *Pmay be an early event during urocystic tumorigenesis and
this should be further evaluated as a tumorigenesis marker
for early detection of bladder cancer [36]. Askham et al.
[37] reported the occurrence of an Akt1 mutation in blad-
der tumors. The Akt1 G49A (E17K) mutation was found
in 2/44 (4.8%) of bladder cancer cell lines and 5/184
(2.7%) of bladder tumors. Cell lines expressing mutant
Akt1 show constitutive Akt1 activation under conditions
of growth factor withdrawal. In our study, the expression
of Bcl-w and Akt1 proteins in 41 bladder cancer speci-
mens and adjacent normal tissues was detected by
Western blot assay. We found that Bcl-w and Akt1 pro-
teins were significantly overexpressed in bladder cancer
tissues versus adjacent normal tissues. This result is in
accordance with previous research.
Melissa et al. reported that MiR-133b down-regulated
the expression of MCL-1 and Bcl-w in lung adenocarcin-
oma cells, and overexpression of miR-133b increased the
sensitivity of lung adenocarcinoma cells to gemcitabine
[38]. We found the expression of Akt1 protein and mRNA
in T24 cells was down-regulated and up-regulated, re-
spectively, after transfection of miR-133b mimics or in-
hibitor. The expression of Bcl-w protein in T24 cells was
down-regulated and up-regulated after transfection of
miR-133b mimics or inhibitor, respectively, but there was
no significant difference in Bcl-w mRNA expression.
In conclusion, in this paper we show that miR-133b
expression is downregulated in bladder cancer tissues
and is linked to high-grade bladder cancer. We show
that miR-133b inhibits cell proliferation and induces
apoptosis in a human bladder cancer cell line, T24. We
found Bcl-w and Akt1 to be putative targets of miR-
133b and show increased expression of these proteins inb
were untreated or transfected with miR-133b-sense- negative control
ransfected with miR-133b-antisense-negative control (NC) or miR-133b
< 0.05.
Figure 8 The effect of miR-133b on T24 cell apoptosis. (a) The effects of miR-133b-sense transfection on apoptosis of T24 cells: (a) untreated
group, (b) miR-133b-sense-negative control (NC) group and (c) miR-133b-sense group. (b) The effects of miR-133b-antisense transfections on
apoptosis of T24 cells: (a) untreated group, (b) miR-133b-antisense-normal control (NC) group and (c) miR-133b-antisense group. Apoptosis was
measured by flow cytometric analysis of T24 cells stained with Annexin V-FITC 24 h after transfection.
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Bcl-w and Akt1 in cultured T24 cells and we therefore
speculated that miR-133b affects the biological behavior
of bladder cancer by regulating the expression of Bcl-w
and Akt1. However, mi-R133b’s specific role in bladder




Forty-one specimens of urothelial bladder cancer and
adjacent normal tissue (more than 5 cm away from the
tumor) were obtained from the Department of Urology,
Shengjing Hospital of China Medical University, be-
tween December 2008 and December 2010. This studywas approved by our institution’s Research Ethics Com-
mittee; informed consent was obtained from each patient.
The age of patients ranged from 43 to 87 years, mean
62.3 ± 6.7 years, and included 29 males and 12 females.
The histological grade and clinical stage were deter-
mined according to World Health Organization WHO
(2004) pathological grading standards and the International
Union Against Cancer UICC (2002) TNM clinical staging
system.
Cell culture and transfection
The human bladder cancer cell line T24 was obtained
from the typical cell culture collection Committee of the
Chinese Academy of Sciences Library (Shanghai, China).
The cells were cultured in RPMI-1640 medium (HyClone,
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FBS (JRH Biosciences, Lenexa, KS, USA), 100 U/ml peni-
cillin, and 100 mg/L streptomycin. Cultures were main-
tained in a humidified atmosphere of 5% CO2 at 37°C.
The following oligonucleotides were purchased from
GenePharma (Shanghai, China): double-stranded miR-
133b sense (mimics) and miR-133b-sense-negative control
(NC); miR-133b -antisense (inhibitor) and miR-133b-
antisense-negative control (NC); and sequences are as
follows: miR-133b, 5′- UUUGGUCCCCUUCAACCAG
CUA-3′, 5′-GCUGGUUGAAGGGGACCAAAUU-3′ and
its NC 5′-UUCUCCGAACGUGUCACGUTT-3′, 5′- AC
GUGACACGUUCGGAGAATT-3′; miR-133b-antisense,
5′-UAGCUGGUUGAAGGGGACCAAA-3′ and its NC
5′-CAGUACUUUUGUGUAGUACAA-3′. The day before
transfection, cells were seeded in antibiotic-free medium.
MiR-133b-sense, miR-133b-sense-NC, miR-133b-antisense
and miR-133b-antisense-NC transfections were carried out
using Lipofectamine 2000 in accordance with the manufac-
turer’s guidelines (Invitrogen). Untreated cells were desig-
nated as the control group.
miR-133b target gene prediction
Computer-based programs were used to predict poten-
tial miR-133 targets. Using “has-miR-133b” as a search
term, we queried PicTar (http://pictar.mdc-berlin.de/),
TargetScan (http://www.targetscan.org/), miRWalk (http://
www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) miRanda
(http://www.microrna.org/microrna/home.do), DIANA-
microT (http://diana.cslab.ece.ntua.gr/microT/) and PITA
(http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html).
Luciferase reporter assay
The target sequences of Bcl-w and Akt1 wild type 3′
UTR were cloned into a luciferase vector which con-
tained the Renilla luciferase gene. In addition, mutant 3′
UTR was also cloned. HEK-293Tcells were cotransfected
with miR-NC or miR-133b mimics using Lipofectamine
2000 (Invitrogen). Cells were collected 48 h after trans-
fection and analyzed using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI), and luciferase
activity values were normalized relative to that of the
Renilla luciferase internal control.
Quantitative Real Time (RT)-PCR (qRT-PCR)
MiRNA of 41 bladder cancer specimens paired to adja-
cent normal bladder tissues were extracted using the
mirVana miRNA Isolation Kit (Ambion, United States)
according to the manufacturer’s instructions. Expression
levels of miR-133b were analyzed by using stem-loop
RT-PCR. MiR-133b stem-loop primer and U6 primer
were purchased from Beijing Microread Gene Technol-
ogy (Beijing, China). PrimeScript®RT reagent Kit and
SYBR®Premix Ex Taq™ were purchased from TaKaRa(Otsu, Japan). U6 RNA was used as an internal control to
normalize the relative abundance of miR-133b. The ex-
pression levels of Bcl-w and Akt1 mRNA were measured
in T24 cells transfected with miR-133b-sense, miR-133b-
sense-NC, miR-133b-antisense and miR-133b-antisense-





TGCCCGTCCTTGT-3′ [39]; and Bcl-w, 5′CACCCA
GGT CTCCGATGAAC3′/5′TTGTTGACACTCTCA GC
ACAC3′ [40]. PCR cycles were as follows: 37°C for 15 min,
85°C for 5 s for reverse transcription, followed by 40 cycles
of 95°C for 10 s, 95°C for 5 s, 61°C for 20 s. Cycle threshold
(Ct) values were collected at the end of each PCR. Each
sample was tested in triplicate, and the relative quantifica-
tion equation (RQ = 2-ΔΔCT) was used to calculate the
relative expression.
Western blot analysis
Western blot analysis of Bcl-w and Akt1 proteins was
conducted in 41 bladder cancer specimens paired to ad-
jacent normal tissues, and also in a T24 cell line. Tissue
and cell protein concentrations were determined using
the Enhanced BCA Protein Assay Kit (Beyotime, Shanghai,
China); equal amounts of proteins (20–30 μg) were sep-
arated by 15% SDS-polyacrylamide gel (SDS-PAGE) and
transferred to PVDF membranes. After incubation with
specific primary antibodies overnight at 4°C, membranes
were further incubated for 1 hour with horseradish
peroxidase-conjugated secondary antibodies. Integrated
density values were analyzed using Fluor Chen 2.0 soft-
ware (Olympus, Yokohama, Japan) and normalized
to those of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
Cell counting kit-8
Cell proliferation analysis was performed using the Cell
Counting Kit-8 (CCK-8) (Tongren, Shanghai, China).
The optimum reaction time of CCK-8 was determined
to be 2.5 h. When 80% confluent, T24 cells (100 μL/well)
were seeded into 96-well plates, and were left untrans-
fected or transfected with miR-133b-sense or miR-133b-
antisense, and further incubated for 12, 24, 48, and
72 hours using three replicates. Approximately 10 μL of
tetrazolium salt, WST-8, was added to each well for
1 hour. The optical density (OD), at 450 nm, of each
well was determined by microplate reader.
Flow cytometric analysis
Apoptosis analysis was performed using a BioVision
Annexin V-FITC reagent kit (Sigma-Aldrich; St. Louis,
MO, USA) and flow cytometry. T24 cells were seeded
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or miR-133b-antisense at 80% confluency. After trans-
fection, cells were trypsinised and washed twice with
PBS (2000 rpm/min, 5 min). Cells (1–5 × 105) were col-
lected, then 500 μL binding buffer, 5 μL Annexin V-
FITC and 5 μL propidium iodide were added. Cells were
incubated for 5–15 min after mixing, and flow cytometry
carried out within an hour.
Statistical analysis
Statistical analysis of data was performed using SPSS19.0
software. Statistical evaluation was performed using one-
way analysis of variance (ANOVA; P < 0.05) and Stu-
dent’s t-test. All data from experiments were expressed
as mean ± SD unless otherwise stated.
Abbreviations
miRNA: microRNA; miR133b: microRNA -133b; UTRs: Untranslated regions;
NC: Negative control; CCK-8: Cell counting kit-8; OD: Optical density.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XC and BW were involved in the concept and in the design, analysis and
interpretation of the data and drafting of the manuscript. XC performed all
the experiments and acquired the data. KW and ZX both participated in
Western blotting assays and RT-PCR. SL and QL performed miR-133b target
gene predictions, cell culture, transfections and dual luciferase reporter assays.
DF and XW conducted cell counts with CCK-8, flow cytometric analysis and
statistical analysis. All authors read and approved the final manuscript.
Acknowledgments
This study was financially supported (project F13-316-1-02) through the
Shenyang Science and Technology Program. We give special thanks to all
the teachers at the Department of Urology of Shengjing Hospital for their
help and support.
Received: 28 December 2013 Accepted: 10 July 2014
Published: 19 July 2014
References
1. Wu L, Fan J, Belasco JG: MicroRNAs direct rapid deadenylation of mRNA.
Proc Natl Acad Sci U S A 2006, 103(11):4034–4039.
2. Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key players in the
immune system, differentiation, tumorigenesis and cell death. Oncogene
2008, 27(45):5959–5974.
3. Zhang B, Pan X, Cobb GP, Anderson TA: MicroRNAs as oncogenes and
tumor suppressors. Dev Biol 2007, 302(1):1–12.
4. Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H:
Differential miRNA expression profiles in bladder urothelial carcinomas.
Asian Pac J Cancer Prev 2010, 11(4):905–911.
5. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larré S, Milo M,
Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL,
Hamdy FC: Distinct MicroRNA alterations characterize high- and
low-grade bladder cancer. Cancer Res 2009, 69(21):8472–8481.
6. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C,
Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R: Micro-RNA
profiling in kidney and bladder cancers. Urol Oncol 2007, 25(5):387–392.
7. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A,
Navarro A, Moreno I, Monzó M, García-Foncillas J: Identification by Real-
time PCR of 13 mature microRNAs differentially expressed in colorectal
cancer and non-tumoral tissues. Mol Cancer 2006, 5:29.
8. Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X,
Hogarty MD: BH3 response profiles from neuroblastoma mitochondria
predict activity of small molecule Bcl-2 family antagonists. Cell Death
Differ 2010, 17(5):872–882.9. Vogler M, Dinsdale D, Dyer MJ, Cohen GM: Bcl-2 inhibitors: small
molecules with a big impact on cancer therapy. Cell Death Differ 2009,
16(3):360–367.
10. O’Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DC, Strasser A:
Tissue expression and subcellular localization of the pro-survival
molecule Bcl-w. Cell Death Differ 2001, 8(5):486–494.
11. Pritchard DM, Print C, O’Reilly L, Adams JM, Potten CS, Hickman JA: Bcl-w is
an important determinant of damage-induced apoptosis in epithelia of
small and large intestine. Oncogene 2000, 19(34):3955–3959.
12. Adams JM, Cory S: The Bcl-2 apoptotic switch in cancer development
and therapy. Oncogene 2007, 26(9):1324–1337.
13. Courchesne SL, Karch C, Pazyra-Murphy MF, Segal RA: Sensory neuropathy
due to loss of Bcl-w. J Neurosci 2011, 31(5):1624–1634.
14. Kumar A, Rajendran V, Sethumadhavan R, Purohit R: AKT kinase pathway: a
leading target in cancer research. ScientificWorldJournal 2013, 2013:756134.
15. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT
pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12):988–1004.
16. Kumar A, Purohit R: Cancer associated E17K mutation causes rapid
conformational drift in AKT1 Pleckstrin Homology (PH) domain. PLoS One
2013, 8(5):e64364.
17. Kim MO, Lee MH, Oi N, Kim SH, Bae KB, Huang Z, Kim DJ, Reddy K, Lee SY,
Park SJ, Kim JY, Xie H, Kundu JK, Ryoo ZY, Bode AM, Surh YJ, Dong Z:
[6]-Shogaol inhibits growth and induces apoptosis of non-small cell lung
cancer cells by directly regulating Akt1/2. Carcinogenesis 2013 . Epub
ahead of print.
18. Gai L, Cai N, Wang L, Xu X, Kong X: Ursolic acid induces apoptosis via Akt/
NF-κB signaling suppression in T24 human bladder cancer cells. Mol Med
Rep 2013, 7(5):1673–1677.
19. Juanpere N, Agell L, Lorenzo M, De Muga S, López-Vilaró L, Murillo R, Mojal
S, Serrano S, Lorente JA, Lloreta J, Hernández S: Mutations in FGFR3 and
PIK3CA, singly or combined with RAS and AKT1, are associated with AKT
but not with MAPK pathway activation in urothelial bladder cancer. Hum
Pathol 2012, 43(10):1573–1582.
20. Lin PY, Yang PC: Circulating miRNA signature for early diagnosis of lung
cancer. EMBO Mol Med 2011, 3(8):436–437.
21. Parasramka MA, Ho E, Williams DE, Dashwood RH: MicroRNAs, diet, and
cancer: new mechanistic insights on the epigenetic actions of
phytochemicals. Mol Carcinog 2012, 51(3):213–230.
22. Hummel R, Maurer J, Haier J: MicroRNAs in brain tumors: a new diagnostic
and therapeutic perspective? Mol Neurobiol 2011, 44(3):223–234.
23. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116(2):281–297.
24. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer 2006, 6(4):259–269.
25. Ambros V: MicroRNA pathways in flies and worms: growth, death, fat,
stress, and timing. Cell 2003, 113(6):673–676.
26. Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andrén O,
Olsson B, Klinga-Levan K: A miRNA expression signature that separates
between normal and malignant prostate tissues. Cancer Cell Int 2011,
11(1):14.
27. Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA,
McLaughlin S, Libertino JA, Whitney D, Summerhayes IC: A microRNA
expression ratio defining the invasive phenotype in bladder tumors.
Urol Oncol 2010, 28(1):39–48.
28. Baffa R, Fassan M, Volinia S, O’Hara B, Liu CG, Palazzo JP, Gardiman M,
Rugge M, Gomella LG, Croce CM, Rosenberg A: MicroRNA expression
profiling of human metastatic cancers identifies cancer gene targets.
J Pathol 2009, 219(2):214–221.
29. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F,
Chebil G, Gudjonsson S, Borg A, Månsson W, Rovira C, Höglund M: MiRNA
expression in urothelial carcinomas: important roles of miR-10a, miR-222,
miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent
homozygous losses of miR-31. Int J Cancer 2009, 124(9):2236–2242.
30. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T,
Enokida H, Nakagawa M, Matsubara H: MiR-145, miR-133a and miR-133b:
tumor-suppr-Essive miRNAs target FSCN1 in esophageal squamous cell
carcinoma. Int J Cancer 2010, 127(12):2804–2814.
31. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K,
Fujimura L, Kikkawa N, Seki N, Nakagawa M: MiR-145 and mrR-133a
function as tumor suppressors and directly regulate FSCN1 expression in
bladder cancer. Br J Cancer 2010, 102(5):883–891.
Chen et al. Cancer Cell International 2014, 4:70 Page 11 of 11
http://www.cancerci.com/content/4/1/7032. Hu G, Chen D, Li X, Yang K, Wang H, Wu W: miR-133b regulates the MET
proto-oncogene and inhibits the growth of colorectal cancer cells
in vitro and in vivo. Cancer Biol Ther 2010, 10(2):190–197.
33. Lee HW, Lee SS, Lee SJ, Um HD: Bcl-w is expressed in a majority of
infiltrative gastric adenocarcinomas and suppresses the cancer cell
death by blocking stress-activated protein kinase/c-Jun NH2-terminal
kinase activation. Cancer Res 2003, 63(5):1093–1100.
34. Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, Um HD: Bcl-w
promotes gastric cancer cell invasion by inducing matrix
metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and
Sp1. Cancer Res 2006, 66(10):4991–4995.
35. Guo WJ, Wang AY, Gao C: Apoptosis and expression of apoptosis-related
proteins Bcl-2, Bcl-xL and Bcl-w in human colon adenocarcinoma. World
Chin J Degestology 2009, 17(25):2589–2594.
36. Sun XF, Sun ZY, Pan B, Li L, Shen W: Alteration in methylation pattern of
oncogene Akt1 promoter region in bladder cancer. Mol Biol Rep 2012,
39(5):5631–5636.
37. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA:
AKT1 mutations in bladder cancer: identification of a novel oncogenic
mutation that can co-operate with E17K. Oncogene 2010, 29(1):150–155.
38. Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA,
Nana-Sinkam SP: microRNA 133B targets prosurvival molecules MCL-1 and
BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009, 388(3):483–489.
39. Wei Y, Hegarty JP, Berg A, Chen X, West G, Kelly AA, Wang Y, Poritz LS,
Koltun WA, Lin Z: NKX2-3 transcriptional regulation of endothelin-1 and
VEGF signaling in human intestinal microvascular endothelial cells. PLoS
One 2011, 6(5):e20454.
40. Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J, Fang L: miR-497 induces
apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 2012,
3(3):475–480.
doi:10.1186/s12935-014-0070-3
Cite this article as: Chen et al.: MiR-133b regulates bladder cancer cell
proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell
International 2014 4:70.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
